[Equine immunoglobulin F(ab’)2 fragments (hyperimmune equine serum) for COVID-19]

Mengarelli C, Bardach A, Alfie V, Klappenbach R, Pichon Riviere A, Augustovski F, Garcia Marti S, Alcaraz A, Ciapponi A
Record ID 32018002308
Original Title: Inmunoglobulinas equinas fragmentos (Fab’)2 (suero equino hiperinmune) en COVID-19
Authors' recommendations: Low-quality evidence, mainly because it comes from a single clinical trial with not enough statistical power to detect differences in primary outcome, did not show that treatment with equine immunoglobulin F(ab’)2 fragments (hyperimmune equine serum) is better than placebo regarding clinical response at 28 days or mortality reduction. The study was conducted in COVID-19 hospitalized patients with moderate-severe disease who did not require mechanical ventilation. Benefits were observed in some of the study secondary outcomes, in clinical response at 7 and 14 days; there was also a trend to reduced mortality in the subgroup of patients with severe disease.
Project Status: Completed
Year Published: 2021
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: Argentina
MeSH Terms
  • Coronavirus Infections
  • COVID-19
  • Immunoglobulin Fab Fragments
  • SARS-CoV-2
  • Antibodies, Neutralizing
  • Horses
Organisation Name: Institute for Clinical Effectiveness and Health Policy
Contact Address: Dr. Emilio Ravignani 2024, Buenos Aires - Argentina, C1414 CABA
Contact Name: info@iecs.org.ar
Contact Email: info@iecs.org.ar
Copyright: Institute for Clinical Effectiveness and Health Policy (IECS)
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.